ATE235914T1 - Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen - Google Patents

Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Info

Publication number
ATE235914T1
ATE235914T1 AT96923511T AT96923511T ATE235914T1 AT E235914 T1 ATE235914 T1 AT E235914T1 AT 96923511 T AT96923511 T AT 96923511T AT 96923511 T AT96923511 T AT 96923511T AT E235914 T1 ATE235914 T1 AT E235914T1
Authority
AT
Austria
Prior art keywords
progression
inhibiting
neuropathic pain
achieveing
analgesia
Prior art date
Application number
AT96923511T
Other languages
German (de)
English (en)
Inventor
Gary Arthur Amstutz
Stephen Scott Bowersox
Kishorchandra Gohil
Peter Isadore Adriaenssens
Ramasharma Kristipati
Theresa Gadbois
Mark Raymond Pettus
Robert R Luther
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE235914T1 publication Critical patent/ATE235914T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Saccharide Compounds (AREA)
AT96923511T 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen ATE235914T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia
PCT/US1996/011041 WO1997001351A1 (en) 1995-06-27 1996-06-26 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Publications (1)

Publication Number Publication Date
ATE235914T1 true ATE235914T1 (de) 2003-04-15

Family

ID=27052304

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96923511T ATE235914T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
AT03007342T ATE359086T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03007342T ATE359086T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Country Status (13)

Country Link
EP (2) EP1336409B1 (enExample)
JP (1) JP2838073B2 (enExample)
AT (2) ATE235914T1 (enExample)
AU (1) AU695166B2 (enExample)
CA (1) CA2224795C (enExample)
DE (3) DE69637021T2 (enExample)
DK (2) DK1336409T3 (enExample)
ES (2) ES2194998T3 (enExample)
FR (1) FR05C0027I2 (enExample)
LU (1) LU91181I2 (enExample)
NL (1) NL300201I2 (enExample)
PT (2) PT835126E (enExample)
WO (1) WO1997001351A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
JP2002509080A (ja) * 1998-02-20 2002-03-26 シンジェンタ リミテッド グラモストラ・スパチュラタの毒から得られる鎮痛性ペプチドおよびその使用
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
WO2004050690A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-I)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004028678D1 (de) 2003-01-28 2010-09-23 Ironwood Pharmaceuticals Inc Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
JP2007507538A (ja) 2003-10-02 2007-03-29 エラン ファーマシューティカルズ，インコーポレイテッド 疼痛軽減方法
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
US8673856B2 (en) * 2006-11-04 2014-03-18 Anygen Co., Ltd. Omega conotoxins
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
KR20220042487A (ko) 2008-12-31 2022-04-05 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP6392754B2 (ja) 2012-08-21 2018-09-19 アーデリクス，インコーポレーテッド 体液貯留又は塩過負荷に関係する疾患及び消化管疾患の治療におけるｎｈｅ仲介の逆輸送を阻害するための化合物並びに方法
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
BR112015025805A2 (pt) 2013-04-12 2017-07-25 Ardelyx Inc compostos de ligação de nh3 e métodos para inibir o transporte de fosfato
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
BR112019013963A2 (pt) 2017-01-09 2020-04-28 Ardelyx Inc inibidores de antiporte mediado por nhe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
WO1993013128A1 (en) * 1991-12-30 1993-07-08 Neurex Corporation Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
AU6400296A (en) 1997-01-30
DE69637021D1 (de) 2007-05-24
EP1336409A1 (en) 2003-08-20
DE69627153D1 (de) 2003-05-08
DE69627153T2 (de) 2003-12-04
EP0835126A1 (en) 1998-04-15
NL300201I2 (nl) 2006-02-01
EP1336409B1 (en) 2007-04-11
JP2838073B2 (ja) 1998-12-16
DE69637021T2 (de) 2008-01-10
DE122005000043I1 (de) 2006-06-29
DE122005000043I2 (de) 2006-08-03
FR05C0027I2 (enExample) 2006-12-29
PT1336409E (pt) 2007-06-29
EP0835126B1 (en) 2003-04-02
CA2224795A1 (en) 1997-01-16
CA2224795C (en) 2001-04-03
AU695166B2 (en) 1998-08-06
ES2194998T3 (es) 2003-12-01
WO1997001351A1 (en) 1997-01-16
HK1058146A1 (en) 2004-05-07
LU91181I2 (fr) 2005-09-06
PT835126E (pt) 2003-07-31
ATE359086T1 (de) 2007-05-15
FR05C0027I1 (enExample) 2005-08-12
ES2283671T3 (es) 2007-11-01
JPH09104634A (ja) 1997-04-22
DK1336409T3 (da) 2007-08-13
DK0835126T3 (da) 2003-07-14
NL300201I1 (nl) 2005-09-01

Similar Documents

Publication Publication Date Title
ATE359086T1 (de) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
HU9701059D0 (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
MY131458A (en) Pyrolopyrimidine compounds
MX9709915A (es) Heterociclos de peptidilo y composiciones que los contienen, utiles en el tratamiento de trastornos relacionados con trombina, y uso de los mismos.
DE69117117D1 (de) Reinigungszusammensetzung zur Vorbeugung und Milderung von Hautreizungen
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69424806D1 (de) Vorrichtung zur Herstellung von Stempeln
DE59309089D1 (de) Lichtempfindliches Gemisch zur Herstellung von Relief- und Druckformen
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DK0743060T3 (da) Anvendelse af tandplejemidler indeholdende bovint colostrum
DE59408857D1 (de) Vorrichtung zur kontinuierlichen Herstellung von Polyacetalen und ihre Verwendung
LV11940A (lv) Melatonina pielietojums personu arstesanai kuras cies no zalu atkaribas
DE69402105D1 (de) Vorrichtung zur Herstellung von Elektreten
FR2710539B1 (fr) Ensemble d'aiguille chirurgicale.
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE59503886D1 (de) Vorrichtung zur herstellung von teigbändern
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ZA961897B (en) 6,7-substituted-2-aminotetralines and use thereof
NO984964L (no) Anvendelse av fosfonsyreestere for behandling av funksjonelle forstyrrelser i hjernen og ved depresjon
ATA217894A (de) Vorrichtung zur herstellung von brezeln
DE69407091D1 (de) Vorrichtung zur Herstellung von Ziegelsteinen